Celebrity-backed cancer treatment venture eyes London listing

Hikma produces generic drugs

A cancer drug venture backed by a group of celebrity investors and Middle Eastern wealth is planning to list on the London Stock Exchange.

Ellipses Pharma, a clinical-stage oncology venture founded by renowned British biotech entrepreneur Sir Chris Evans and, is preparing to reverse into a brand-new company, targeting a listing valuation of between £450m and £500m, according to reports in The Times.

The company’s investors include Evans, founder of housebuilder Redrow, Steve Morgan, and Scottish entrepreneur Sir Tom Hunter’s investment vehicle West Coast Capital.

Celebrity investors have also thrown their weight behind Ellipses, including comedian Jimmy Carr and Andrew Lloyd Webber.

But the venture’s single largest investor is Abu Dhabi’s sovereign wealth fund, which holds a 45 per cent stake. Waleed al- Mokarrab al-Muhairi, deputy chief executive of Mubadala Investment Company, the nation’s sovereign wealth fund, sat on the firm’s board until March 2025.

Stay in the know

Three daily briefings with the key market moves and top business and political stories.

SUBSCRIBE HERE

It launched a clinical trial programme in the UAE in December 2024.

Seeing off the US

Evans, who has overseen the founding and listing of numerous biotech companies including Enzymatix and Celsis, had been weighing up a listing away from London.

The entrepreneur was considering the Nasdaq for Ellipses’ home, while Hong Kong was also floated as a possible venue in 2025.

But Ellipses is now targeting a listing in London as soon as February through a reverse takeover of Wolfram Resources, a cash shell which had been focused on investment in precious metals exploration across central Asia.

Private bank Berenberg is reported to have been appointed to help manage the deal, while Ellipses is also preparing to appoint non-executives to its board before a listing.

Royal Bank of Canada and Pharma Ventures, an M&A advisory firm, are understood to have been lined up to advise on potential out-license deals with big pharma companies. A formal announcement could be made as soon as this week.

Boost for London

Reverse takeovers offer a fast-track route to raising money on public markets compared to an initial public offering and the Nasdaq has been hit with a flurry of such deals over the course of this year.

A successful listing would also provide London with a much needed boost, as it continues to feel the shocks of a wave of delistings coupled with a continued exodus of IPOs.

In particular, it would lift London’s biotech and pharmaceutical sector, which has seen companies eye opportunities in America. FTSE heavyweight Astrazeneca has pivoted closer to the US over the last year, upgrading its listing on the New York stock Exchange.

Ellipses employs around 40 people, mainly from big pharma companies, and has invested roughly £185m in its drug pipeline.

Original source Celebrity-backed cancer treatment venture eyes London listing

Back to home